These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Measles mortality reduction contributes substantially to reduction of all cause mortality among children less than five years of age, 1990-2008. van den Ent MM; Brown DW; Hoekstra EJ; Christie A; Cochi SL J Infect Dis; 2011 Jul; 204 Suppl 1():S18-23. PubMed ID: 21666160 [TBL] [Abstract][Full Text] [Related]
7. Is measles next? Roberts L Science; 2015 May; 348(6238):958-61, 963. PubMed ID: 26023116 [No Abstract] [Full Text] [Related]
8. Measles immunisation: time to close the gap. The Lancet Infectious Diseases Lancet Infect Dis; 2016 Jan; 16(1):1. PubMed ID: 26738818 [No Abstract] [Full Text] [Related]
9. UN agencies launch new plan to halve mortality of measles. J Adv Nurs; 2001 Oct; 36(1):6-7. PubMed ID: 11601411 [No Abstract] [Full Text] [Related]
10. Global measles deaths plunge by 48% over past six years. Saudi Med J; 2006 Jun; 27(6):918-22. PubMed ID: 16969955 [No Abstract] [Full Text] [Related]
11. Measles vaccination in tropical countries. Griffith AH Trans R Soc Trop Med Hyg; 1975; 69(1):29-30. PubMed ID: 806999 [No Abstract] [Full Text] [Related]
12. [Measles throughout the world]. Gateff C Med Trop (Mars); 1985; 45(1):19-25. PubMed ID: 2581109 [TBL] [Abstract][Full Text] [Related]
13. Experiences in mass prevention of measles by vaccination. Perkins FT Trans R Soc Trop Med Hyg; 1975; 69(1):24-5. PubMed ID: 1145714 [No Abstract] [Full Text] [Related]
14. Global measles elimination efforts: the significance of measles elimination in the United States. Strebel PM; Henao-Restrepo AM; Hoekstra E; Olive JM; Papania MJ; Cochi SL J Infect Dis; 2004 May; 189 Suppl 1():S251-7. PubMed ID: 15106119 [TBL] [Abstract][Full Text] [Related]
16. Will Measles Virus or Humanity Win the International "Fitness" Challenge? Arvin AM Annu Rev Virol; 2019 Sep; 6(1):iii-vii. PubMed ID: 31567068 [No Abstract] [Full Text] [Related]
17. Using cost-effectiveness analysis to support research and development portfolio prioritization for product innovations in measles vaccination. Garrison LP; Bauch CT; Bresnahan BW; Hazlet TK; Kadiyala S; Veenstra DL J Infect Dis; 2011 Jul; 204 Suppl 1():S124-32. PubMed ID: 21666153 [TBL] [Abstract][Full Text] [Related]
18. Experience in global measles control, 1990-2001. Henao-Restrepo AM; Strebel P; John Hoekstra E; Birmingham M; Bilous J J Infect Dis; 2003 May; 187 Suppl 1():S15-21. PubMed ID: 12721887 [TBL] [Abstract][Full Text] [Related]